Physician profile
Deana Platis
NPI 1396271631
$844.16
in general payments reported to CMS, 2019-2025
14 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $216 · 2023: $201 · 2024: $148 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $142.63 | 2021-2024 | |
| Pfizer INC. | $132.50 | 2021-2025 | |
| Rhythm Pharmaceuticals, INC. | $125.00 | 2022 | |
| Phadia US INC. | $90.11 | 2024 | Immunocap |
| Kaleo, INC. | $62.03 | 2023 | Auvi-Q |
| Cranial Technologies, INC | $54.88 | 2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $49.15 | 2025 | |
| Sobi, INC | $42.02 | 2021-2023 | |
| Seqirus USA INC | $35.49 | 2021 | |
| Verrica Pharmaceuticals INC. | $34.65 | 2024 | Ycanth |
| Genentech USA, INC. | $26.07 | 2021 | |
| Alk-Abello, INC | $21.69 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $14.47 | 2023 | Bexsero |
| Merck Sharp & Dohme LLC | $13.47 | 2023 | Gardasil 9, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deana Platis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.